Margin recovery test: Can Dr. Reddy's arrest the slide?
Q1 FY27 missed expectations badly—EPS of ₹6 vs ₹9 consensus, revenue down 5.5% YoY in the US. The Street will watch October 23 for signs that management's 25% EBITDA margin target is still on track, and whether ex-US growth and the biosimilar/GLP-1 shift can offset US generics pricing erosion.
The setup
Dr. Reddy's faces a critical read on October 23. After Q1 FY27 missed badly—EPS of ₹6 versus the ₹9 consensus, and a 5.5% YoY revenue decline in the US—the Street will be asking whether the company can stabilise and execute on its margin recovery plan. Management has committed to restoring EBITDA margins to 25% by FY27 and driving double-digit growth outside the US. Q2 will show if those targets remain credible post-Q1 stumble.
What to expect
~₹740–750 Cr
on-plan ~6% growth ex-Q1 headwinds; US generics pricing remains a drag, ex-US growth tracking double digits
~25% target
trajectory under scrutiny after Q1 margin compression; cost discipline and product mix (biosimilars, GLP-1) key
Targeting >50%
long-term transition toward high-value therapies; Q2 mix will signal progress
A strong quarter would see: (1) revenue in the ₹740–750 Cr range, (2) EBITDA margin holding or improving sequentially toward 25%, (3) signs that ex-US markets are carrying the load (double-digit growth), and (4) initial traction from biosimilar (rituximab, launched post-Q1) and GLP-1 (Semaglutide generics ramp). A weak quarter would show: (1) revenue below ₹730 Cr, (2) margin compression or stalling recovery, (3) continued US market de-growth or pricing pressure unexpectedly worsening, (4) no progress on biosimilar/GLP-1 mix shift, or (5) USFDA compliance concerns slowing approvals.
On track?
Q1 FY27's miss was a speed bump. Revenue at ₹708 Cr fell short of expectations; the EPS miss (₹6 vs ₹9 consensus) flagged both top-line softness and margin pressure. For Q2 to rebuild confidence, it must show that Q1 was a trough, not a trend. Management guidance remains intact—25% EBITDA by FY27, double-digit ex-US growth—but execution risk has risen. The Street will be watching for any downward revision to FY27 targets or a slowdown in margin recovery timelines.
What the Street says
Since last quarter
Business updates: FDA approval of rituximab biosimilar (August 2026) strengthens the biosimilar portfolio. Partnerships with Takeda (dengue vaccine, Qdenga® distribution in India, September 2026) and Gilead (lenacapavir HIV prevention drug licensing, September 2026) expand the product mix. Generic bosutinib 400mg launched in the US, targeting the $585M oncology segment—a near-term revenue driver.
Regulatory & compliance: USFDA Pre-Approval Inspections (PAI) at FTO-9 (Visakhapatnam, October 8–9) and FTO-11 (Pydibhimavaram, October 8) yielded observations. Mexico facility underwent records assessment (September 2026). UK API facility inspection closed as VAI (Voluntary Action Indicated, August 2026). These are routine in the pharma cycle, but the cluster warrants monitoring for any delays to pending approvals.
Management & corporate: CEO of API & Services, Deepak Sapra, resigned (August 2026). Global Head of Biologics, Dr. Sridevi Khambhampaty, appointed concurrently. The reshuffle signals a strategic pivot toward high-margin biologics and away from commodity APIs. Ownership: ICICI Prudential MF crossed 5% stake (August 2026). FII ownership declined 101 bps QoQ to 32.07%, while DII rose to 31.74%, signalling cautious institutional positioning ahead of the result.
Close
Dr. Reddy's Q2 FY27 result is a margin-recovery test. After Q1's miss, the Street needs proof that the 25% EBITDA target and double-digit ex-US growth are still on the rails. Positive momentum would hinge on three things: (1) revenue trending ₹740–750 Cr (stabilisation post-Q1), (2) EBITDA margin returning toward the guidance track, and (3) initial traction from biosimilar launches and partnership revenues (Takeda, Gilead). Keep an eye on US generics commentary—if pricing pressure has worsened or Q1 was not truly a trough, guidance may face downward revision. Regulatory compliance updates on recent USFDA inspections will also weigh on market sentiment.
Informational and educational content only. Not investment advice.